Assessing the Impact of TAILORx on Breast Cancer Management.

The landmark TAILORx trial has dramatically changed the way patients with estrogen receptor-positive cancer are treated. Continued analyses from the trial have further stratified clinical risk for a subset of women who are 50 years or younger, based on their OncotypeDX Breast Recurrence Score. ONCOLOGY® recently sat down with Jane L. Meisel, MD, of Emory University School of Medicine in Atlanta, Georgia, to discuss how these data from the TAILORx trial validate and inform the current and future care of patients with breast cancer.